John Patrick Shannon Jr.
See Remarks at Xeris Biopharma Holdings Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Xeris Biopharma Holdings Inc., 2 years.
Xeris Biopharma Holdings Inc.
Director · See Remarks
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 31, 2026 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −118,134 | $7.36 | $869,466 |
| Jan 31, 2026 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −111,621 | $7.36 | $821,531 |
| Jan 31, 2026 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −110,750 | $7.36 | $815,120 |
| Jan 30, 2026 | Xeris Biopharma Holdings Inc. | Grant or award | +478,436 | — | — |
| Jan 5, 2026 | Xeris Biopharma Holdings Inc. | Open-market sale | −24,907 | $7.08 | $176,342 |
| Jan 5, 2026 | Xeris Biopharma Holdings Inc. | Option exercise | +64,265 | $1.55 | $99,611 |
| Jan 5, 2026 | Xeris Biopharma Holdings Inc. | Option exercise | +25,136 | $1.55 | $38,961 |
| Jan 5, 2026 | Xeris Biopharma Holdings Inc. | Option exercise | +2,900 | $3.94 | $11,426 |
| Nov 14, 2025 | Xeris Biopharma Holdings Inc. | Option exercise | +87,100 | $1.55 | $135,005 |
| Nov 13, 2025 | Xeris Biopharma Holdings Inc. | Option exercise | +8,970 | $1.55 | $13,904 |
| Nov 13, 2025 | Xeris Biopharma Holdings Inc. | Open-market sale | −23,242 | $7.46 | $173,385 |
| Aug 1, 2025 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −36,918 | $5.38 | $198,619 |
| Jan 31, 2025 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −110,750 | $3.56 | $394,270 |
| Jan 31, 2025 | Xeris Biopharma Holdings Inc. | Shares withheld for tax | −110,750 | $3.56 | $394,270 |
| Jan 31, 2025 | Xeris Biopharma Holdings Inc. | Grant or award | +800,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.